Cord Blood News Volume 8.00 | Jan 7 2016

Potency of Umbilical Cord Blood- and Wharton’s Jelly-Derived Mesenchymal Stem Cells for Scarless Wound Healing
Umbilical cord blood (UCB)-MSCs expressed lower levels of the pre-inflammatory cytokines IL1A and IL1B, but higher levels of the extracellular matrix-degradation enzymes MMP1 and PLAU compared with Wharton’s jelly-MSCs, suggesting that UCB-MSCs were more likely to favor scarless wound healing. [Sci Rep] Full Article

Discovery of Novel INK4C Small-Molecule Inhibitors to Promote Human and Murine Hematopoietic Stem Cell Ex Vivo Expansion
Researchers identified a lead p18 inhibitor, XIE18-6, confirmed its p18-targeting specificity and bioactivity of promoting hematopoietic stem cells expansion, and then performed structure-activity relationship (SAR) studies by synthesizing a series of analogs of XIE18-6. [Sci Rep] Full Article

Transplantation of Placenta-Derived Mesenchymal Stem Cells Reduces Hypoxic-Ischemic Brain Damage in Rats by Ameliorating the Inflammatory Response
Investigators explored the immunoregulatory mechanism of placenta-derived mesenchymal stem cells (PD-MSCs) in hypoxic-ischemic brain damage treatment. PD-MSC treatment inhibited the production of pro-inflammatory cytokines and increased the production of interleukin-10 in the ischemic hemispheres and peripheral blood serum. [Cell Mol Immunol] Abstract

MiR-26b-3p Regulates Human Umbilical Cord Derived Mesenchymal Stem Cell Proliferation by Targeting Estrogen Receptor Alpha
Researchers explored the roles of miRNAs in regulating the in vitro proliferation of human umbilical cord derived mesenchymal stromal cells (hUC-MSC). They found that miR-26b-3p was significantly up-regulated during serial in vitro passage of hUC-MSC and was correlated with cellular senescence and cell cycle genes. [Stem Cells Dev] Abstract

Human Umbilical Cord Mesenchymal Stem Cells Delivering sTRAIL Home to Lung Cancer Mediated by MCP-1/CCR2 Axis and Exhibit Antitumor Effects
The migration of human umbilical cord mesenchymal stem cells to lung cancer was observed through transwell migration assay and animal bioluminescent imaging both in vitro and in vivo. [Tumor Biol] Abstract

Chondrogenic Induction of Mesenchymal Stromal/Stem Cells from Wharton’s Jelly Embedded in Alginate Hydrogel and without Added Growth Factor: An Alternative Stem Cell Source for Cartilage Tissue Engineering
Investigators evaluated chondrogenic differentiation of Wharton’s jelly-mesenchymal stromal/stem cells (WJ-MSC) on three-dimensional scaffolds, without adding growth factors, at transcript and protein levels. Once seeded in the hydrogel scaffold, WJ-MSCs and bone marrow-MSCs have different profiles of chondrogenic differentiation at both the phenotypic level and matrix synthesis. [Stem Cell Res Ther] Full Article

Glial Cell Line-Derived Neurotrophic Factor Induced the Differentiation of Amniotic Fluid-derived Stem Cells into Vascular Endothelial-Like Cells In Vitro
Scientists investigated the effect of an adenovirus-mediated GDNF gene, which was engineered into amniotic fluid-derived stem cells (AFSCs), on the cells’ biological properties and whether GDNF in combination with AFSCs can be directionally differentiated into vascular endothelial-like cells in vitro. [J Mol Histol] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Strategia Therapeutics Announces Progress in a Phase I Clinical Trial of the Anti-Cancer Agent “FF-10501-01” for FUJIFILM in Patients with Advanced Hematologic Malignancies
Strategia Therapeutics, Inc. announced progress in a Phase I clinical trial of FUJIFILM’s anti-cancer agent, FF-10501-01 in the United States in patients with relapsed or refractory myelodysplastic syndromes and acute myeloid leukemia. [Strategia Therapeutics, Inc.] Press Release

Creative Medical Health Granted U.S. Patent for Heart Failure Stem Cell Therapy
Creative Medical Health Inc. announced issuance of U.S. Patent #9,205,112, titled “Combination Therapy of Cardiovascular Disease” by the United States Patent and Trademark Office. The patent covers the use of adult stem cells such as cord blood and mesenchymal stem cells in combination with modulation of oxidative stress in treatment of heart failure [Creative Medical Health Inc. (BusinessWire)] Press Release

From our sponsor: Learn how to form and isolate neural rosettes more efficiently. Watch the video.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

NEW Research Specialist – Stem Cells from the Hematopoietic System (Howard Hughes Medical Institute)

NEW Doctoral Fellow – Stem Cell Research (Krembil Research Institute)

NEW Postdoctoral position – Regenerative Medicine (University of Copenhagen)

NEW Stem Cell Scientist and Postdoctoral Positions (National Center for Advancing Translational Science)

Postdoctoral Position – Cell and Molecular Biology of Leukemia (Virginia Commonwealth University)

Postdoctoral Research Scientist – Lymphocyte Trafficking Mechanisms in Allogeneic Stem-Cell Transplantation (Columbia University Medical Center)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Assistant Member – Cord Blood Transplantation (Fred Hutchinson Cancer Research Center)

Assistant Member – Cord Blood Transplantation (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.